boultonlab.bsky.social
Boulton Lab
@boultonlab.bsky.social
480 followers 360 following 4 posts
Our diverse lab at @crick.ac.uk studies mechanisms of DNA repair at breaks/forks/telomeres in health & disease | Tweets by lab members unless signed SB | Views own
Posts Media Videos Starter Packs
Reposted by Boulton Lab
ssegurabayona.bsky.social
Sandra Segura-Bayona @ssegurabayona.bsky.social · 1d
🧬 Preprint alert!

"Distinct ATRX functions cooperate with 9-1-1 and CST complexes to safeguard replication and telomere integrity."

Read the manuscript here 👉 www.biorxiv.org/content/10.1...
Distinct ATRX functions cooperate with 9-1-1 and CST complexes to safeguard replication and telomere integrity
Mutations in the ATRX chromatin remodeller predispose to a developmental genetic disorder and cancer, but how it safeguards genome and telomere stability remains unresolved. Here, we uncover critical ...
www.biorxiv.org
1 8 15
boultonlab.bsky.social
Boulton Lab @boultonlab.bsky.social · 27d
New preprint from the lab led by @ssegurabayona.bsky.social identifying SLFN11 activity as a barrier to ALT establishment.
ssegurabayona.bsky.social
Sandra Segura-Bayona @ssegurabayona.bsky.social · 27d
🚀 New preprint alert!

We uncover SLFN11 as a molecular gatekeeper that restricts alternative lengthening of telomeres (ALT) by sensing telomere-associated replication stress and triggering apoptosis.

📄 Read the manuscript here: www.biorxiv.org/content/10.1...
SLFN11 restricts escape from telomere crisis to prevent alternative lengthening of telomeres
The tRNA nuclease SLFN11 is epigenetically silenced in ~50% of treatment-naive tumours and is the strongest predictor of chemoresistance but why it is frequently inactivated in cancer is unknown. To a...
www.biorxiv.org
4
Reposted by Boulton Lab
ssegurabayona.bsky.social
Sandra Segura-Bayona @ssegurabayona.bsky.social · 27d
🚀 New preprint alert!

We uncover SLFN11 as a molecular gatekeeper that restricts alternative lengthening of telomeres (ALT) by sensing telomere-associated replication stress and triggering apoptosis.

📄 Read the manuscript here: www.biorxiv.org/content/10.1...
SLFN11 restricts escape from telomere crisis to prevent alternative lengthening of telomeres
The tRNA nuclease SLFN11 is epigenetically silenced in ~50% of treatment-naive tumours and is the strongest predictor of chemoresistance but why it is frequently inactivated in cancer is unknown. To a...
www.biorxiv.org
1 9 22
Reposted by Boulton Lab
romangp.bsky.social
Román González-Prieto @romangp.bsky.social · May 30
Save de date! Join us at @cabimer.bsky.social on October 17th for the @GenomaHubCSIC Workshop in "Genome Dynamics in Development and Disease". Slots available for talks! Registration opens soon!!
8 7
boultonlab.bsky.social
Boulton Lab @boultonlab.bsky.social · May 27
Chemical biology: www.linkedin.com/jobs/view/42...
Cell biology: www.linkedin.com/jobs/view/42...
Structural biology: www.linkedin.com/jobs/view/42...
boultonlab.bsky.social
Boulton Lab @boultonlab.bsky.social · May 27
We are looking to recruit three posts at the @crick.ac.uk in structural biology, cell biology, and pharmacology to join a 20+ strong multidisciplinary team focused on delivering the first precision medicines for the treatment of ALT cancers. Interested? Please check out the advertised jobs below:
1 4 3
Reposted by Boulton Lab
crick.ac.uk
The Francis Crick Institute @crick.ac.uk · May 21
Read our Q&A with Simon Boulton (@boultonlab.bsky.social), a group leader here at the Crick who co-founded the company Artios in 2016.

Artios is a biotech company that develops cancer treatments that target DNA damage response pathways.
www.crick.ac.uk/news-and-fea...
From the lab to the clinic: developing the next generation of precision cancer therapies
Crick group leader Simon Boulton co-founded Artios in 2016, a spin-out from Cancer Research UK’s Commercial Partnerships, where he is now VP of Science Strategy. Artios develops cancer treatments that...
www.crick.ac.uk
6 9
Reposted by Boulton Lab
scienceboss.bsky.social
Ryan Cross @scienceboss.bsky.social · Apr 29
Artios Pharma presented data on its ATR inhibitor (blocks a key DNA damage response enzyme) at #AACR25 today.

50% response (tumor shrinkage) in patients whose tumors lacked a counterpart DNA repair enzyme called ATM.

Read more in my story for @endpts.com

endpts.com/artios-cance...
Artios drug exploits ‘replication stress’ in cancer, shrinking subset of tumors in early study
Artios Pharma, a startup developing drugs that weaken a tumor’s ability to maintain its DNA, announced positive results in a subset of patients with advanced cancer.
endpts.com
2 6
boultonlab.bsky.social
Boulton Lab @boultonlab.bsky.social · Apr 30
Exciting results were presented by Artios Pharma at the AACR meeting from their STELLA Phase 1/2a study using their ATR inhibitor ART0380 to target ATM low/negative tumours: www.artios.com/press-releas...
Artios Pharma Reports Differentiated Clinical Activity in STELLA Phase 1/2a Study for Lead Program ART0380 at the American Association for Cancer Research (AACR) Annual Meeting 2025 - Artios Pharma
ART0380 in combination with low-dose irinotecan demonstrated a 50% confirmed overall response rate (cORR) in patients with Ataxia-Telangiectasia Mutated (ATM)-negative1 solid tumors at the recommended...
www.artios.com
1 2